Comparative Pharmacology
Head-to-head clinical analysis: ACEBUTOLOL HYDROCHLORIDE versus ZIAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACEBUTOLOL HYDROCHLORIDE versus ZIAC.
ACEBUTOLOL HYDROCHLORIDE vs ZIAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist (cardioselective beta-blocker) with intrinsic sympathomimetic activity (ISA). Competitively blocks catecholamine binding at cardiac beta-1 receptors, reducing heart rate, myocardial contractility, and blood pressure. ISA provides mild beta-receptor stimulation, decreasing the extent of resting bradycardia and lipid changes.
ZIAC is a combination of bisoprolol, a cardioselective beta1-adrenergic receptor blocker, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing blood volume.
Dose: 200-800 mg/day orally in 1-2 divided doses. Initially 200 mg twice daily; may increase to 400 mg twice daily as needed.
ZIAC (bisoprolol fumarate/hydrochlorothiazide) 2.5 mg/6.25 mg to 10 mg/6.25 mg orally once daily, titrated at 2-week intervals based on blood pressure response. Maximum dose: 20 mg/12.5 mg per day.
None Documented
None Documented
3-4 hours for acebutolol; 8-13 hours for diacetolol (active metabolite); clinically significant in renal impairment
Bisoprolol: 9–12 h (terminal); HCTZ: 6–15 h (terminal); prolonged in renal impairment; steady state by 5 days
Renal: 30-40% as unchanged drug and 50-60% as diacetolol; fecal: ~10%
Renal: bisoprolol (50% unchanged), HCTZ (≥95% unchanged); biliary/fecal: bisoprolol (≤2%)
Category C
Category C
Beta Blocker
Beta Blocker + Diuretic